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Background: The optimal antithrombotic regimen for patients with atrial fibrillation (AF) after acute coronary syndrome or coronary stenting (PCI) 
is still unresolved and patients often receive multiple antithrombotic drugs to prevent recurrent thromboembolic events, but at the cost of increased 
risk of bleeding. We examined bleeding risk associated with different antithrombotic regimens in these patients.
Methods: AF patients hospitalized with myocardial infarction (MI) or undergoing PCI between 2001 and 2009 were identified by individual-
level-linkage of nationwide registries. We calculated the incidence rate of major bleeding (requiring hospitalization) according to post-discharge 
antithrombotic treatment regimens.
Results: Of 8,723 subjects included (age 75.4±10.2 years, 61% men), 72% had MI and 28% underwent PCI. Within 1-year 581 (6.2%) bleedings 
were recorded; 54 (9.3%) were fatal. Any combination of vitamin K antagonist (VKA) and antiplatelet drug produced markedly increased rates of 
bleeding relative to other antithrombotic regimens at 90 days, 25.5 vs. 10.9 bleedings/100 person-years, respectively. Risk of bleeding decreased 
during longer treatment, at 6-12 months rates were 9.2 vs. 6.3.
Conclusions: Any dual or triple antiplatelet drug combination with VKA was associated with high bleeding rates during the initial 90 days. Careful 
consideration balancing risk and benefit of antithrombotic combination therapy in AF patients with ischemic heart disease is therefore needed.
